Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer

Cancer Letters

Volumn 262, Issue 2, 2008, Pages 232-238

  Chow, Louis Wing Cheong ^a,b,c   Yip, Adrian Yun San ^b   Loo, Wings Tjing Yung ^c   Toi, Masakazu ^b,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Organisation for Oncology and Translational Research   (Hong Kong)

^c UNIMED Medical Institute   (Hong Kong)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Aromatase; Breast cancer; Neoadjuvant; Signal transduction

Indexed keywords

AROMATASE; FLUORODEOXYGLUCOSE F 18; IMATINIB; LETROZOLE; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER INVASION; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; FEMALE; GASTRITIS; GENERALIZED EDEMA; HEMATOMA; HUMAN; HUMAN TISSUE; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; MALAISE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PRURITUS; RASH; SIGNAL TRANSDUCTION; STOMATITIS; SWELLING; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DRUG EVALUATION; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PILOT PROJECTS; PIPERAZINES; POSTMENOPAUSE; PYRIMIDINES; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 40849137741     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.003     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
3. Chow L.W.C., and Ho P. Hormonal receptor determination of 1052 Chinese breast cancers. J. Surg. Oncol. 75 (2002) 172-175
4. Nabholtz J.M., and Reese D. Anastrozole in the management of breast cancer. Expert Opin. Pharmacother. 3 (2002) 1329-1339
5. Lu Q., Nakmura J., Savinov A., et al. Expression of aromatase protein and messenger ribonucleotide acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 (1996) 3061-3068
6. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 344 (2001) 276-285
7. Thürlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
8. Simoncini T., Hafezi-Moghadam A., and Brazil D.P. Interaction of oestrogen receptor with the regulatory with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
9. Lee A.V., Jackson J.G., Gooch J.L., et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 3 (1999) 787-796
10. Webb P., Lopez G.N., Uht R.M., et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9 (1995) 443-456
11. Font de Mora J., and Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to estrogen receptor. Mol. cell. Biol. 20 (2000) 5041-5047
12. Nicholson R.I., Harper M.E., Hutcheson I.R., et al. ZD1839 (Iressa) improves the antitumor activity of tamoxifen in anti-hormone-responsive breast cancer cells. Clin. Cancer Res. 7 (2001) 3766s
13. Capdeville R., Buchdunger E., Zimmermann J., et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 7 (2002) 493-502
14. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5 (1982) 649-655
15. Hayward J.L., Carbone P.P., Heusen J.C., et al. Assessment of response of therapy in advanced breast cancer. Br. J. Cancer 3 (1997) 292-298
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. Available from: [December, 12 2003].
17. Brueggemeier R.W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 7 (2006) 1919-1930
18. Mokbel R., Karat I., and Mokbel K. Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update. Int. Semin. Surg. Oncol. 3 (2006) 31
19. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348 (2003) 2431-2442
20. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97 (2005) 1262-1271
21. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
22. ATAC Trialists' Group, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet. 365 (2005) 60-62.
23. Clarke R., Liu M.C., Bouker K.B., et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signalling. Oncogene 22 (2003) 7316-7339
24. Moy B., and Goss P.E. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin. Cancer Res. 12 (2006) 4790-4793
25. Chow L.W.C., and Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. Breast Cancer Res. Treat. 94 (2005) S240 abstract
26. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 38 (2002) S83-S87
27. Harrison M.L., and Goldstein D. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Intern. Med. J. 36 (2006) 367-377
28. Kerkelä R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916